James W. Murrough, MD, PhD

Department of Psychiatry, Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York

JCP
Ketamine Infusions and Written Exposure Therapy for Chronic PTSD
Original Research

April 2, 2025

Preliminary findings suggest that the combined treatment may yield large and durable symptom reductions for patients with severe chronic PTSD
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Meta-Analysis

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
, , , et al
JCP
Original Research

April 27, 2021

The pandemic has clearly placed a tremendous strain on health care workers, but how has it affected their ability to function in their daily lives and the likelihood of...
, , , et al
JCP
Meta-Analysis

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
, , , et al
JCP
Educational Activity

July 30, 2019

New mechanisms of action present new opportunities to improve outcomes for patients with depression. Listen to a panel of experts discuss best practices and novel antidepressants at the 2019...
, , , et al
JCP
Original Research

September 2, 2014

, , , et al
JCP
Letter to the Editor

March 15, 2011

, , , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe